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were in the range of those after balloon dilatation followed by DES – stenting (8.3 %).
At one year plain balloon dilation (13.4 %) had a similar rate of re - restenosis as cutting
balloon dilatation (13.4%) and balloon dilatation followed by implantation of a BMS
(15.4 %).
Conclusion: The reported rate of re - restenosis in ISR was generally low but differ
largely according to the applied therapy.
TCT-196
Restenosis Pattern of Drug-Eluting Stent : Impact of Stent Type and Timing
Noriyuki Ohashi, Kazushige Kadota, Tsuyoshi Gotou, Hiroyuki Yamamoto, Yasushi
Fuku, Akitoshi Hirono, Hiroyuki Tanaka, Takeshi Tada, Seiji Habara, Suguru
Ohtsuru, Kazuaki Mitsudo
Cardiology, Kurashiki central hospital, Kurashiki, Japan
Background: Recently, late restenosis after drug-eluting stent (DES) has been
reported. However, the impact of DES type and timing remains unclear. Thus, we
evaluated the restenosis pattern of three different drug-eluting stent ; sirolimus-eluting
stent (SES), paclitaxel-eluting stent (PES), and zotarolimus eluting stent (ZES) in
midterm (8 months) and lateterm (20 months).
Methods: From November 2002 to October 2009, 4368 consecutive patients (7546
lesions) were treated with SES and PES and ZES (SES, 5924 lesions; PES, 1405
lesions; ZES, 217 lesions) and performed midterm follow-up coronary angiography
(f/u CAG) at 6 to 8 months after implantation (f/u rate, 81.6% [6156/7546]). Of these,
4610 lesions without restenosis underwent late f/u CAG at 12 months after early f/u
(f/u rate, 86.2%). Early restenosis was defined as restenosis at midterm f/u and late
restenosis as restenosis at late f/u without early restenosis. Restenosis types are
classified into 1 focal pattern with 4 types and 3 diffuse patterns: pattern Ι (focal: type
IA, gap; type IB, edge; type IC, body; type ID, multifocal), pattern II (diffuse in-stent),
pattern III (diffuse proliferative), and pattern IV (total occlusion).
Results: Data are shown in the table.
Restenosis pattern with Mehran Classification of SES and PES and ZES
*1;SES vs PES, *2;SES vs ZES, *3;PES vs ZES
Conclusion: Restenosis pattern of drug-eluting stent could be depend on stent type
and timing of restenosis.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus-Eluting Coronary Stent System (CSS) with a Bioabsorbable polymer
compared to the Endeavor Zotarolimus-Eluting Coronary Stent System through the
assessment of clinical, angiographic, and IVUS endpoints.
Methods: 149 patients, were randomized 3:1 to receive either the Elixir DESyne BD
Novolimus-eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a
sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to
Endeavor Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of
Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were
analyzed for the primary endpoint of in-stent late lumen loss assessed by QCA at 6
months. Moreover, all patients underwent evaluation for the secondary endpoints which
include Device-oriented Composite Endpoint (DoCE) defined as: cardiac death, MI
not clearly attributable to a non-intervention vessel, and clinically-indicated target
lesion revascularization at 1, 6, 9, and 12 months and annually through 5 years,
clinically-indicated Target Lesion Revascularization (TLR), and Clinically-indicated
Target Vessel Revascularization (TVR). Lesions were also evaluated for angiographic
endpoints at 6 months including: in-lesion late lumen loss, percent diameter stenosis,
minimal lumen diameter post procedure and at 6 months, angiographic binary
restenosis (≥50%), and stent thrombosis. A subset of patients underwent intravascular
ultrasound (IVUS) evaluation including in-stent volumetric neointimal burden and
percent (%) neointimal obstruction at 6 months.
Results: Clinical results through 6 months, as well as the primary endpoint of in-stent
late lumen loss by QCA at 6 months with additional angiographic and IVUS results,
will be presented.
Conclusion: Clinical results through 6 months, as well as the primary endpoint of in-
stent late lumen loss by QCA at 6 months with additional angiographic and IVUS
results will be presented.
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Background: Few data exist that describe percutaneous coronary intervention (PCI)
benefits in COURAGE-like stable coronary disease populations receiving a drug
eluting stent (DES). The aim was to compare, for the first time, clinical and health
status outcomes in COURAGE-like patients following PCI exclusively using a DES,
the XIENCE V® everolimus-eluting stent (Abbott Vascular, Santa Clara, CA).
Methods: This was a prospective, multi-center, unrestricted, real-world study of
consecutively-enrolled patients (n=4797) who had a least 1 valid Seattle Angina
Questionnaire score at baseline. Quality of Life (QoL) scores were analyzed using
Two-Way ANOVA (Mixed Model-Repeated Measures) with group (COURAGE-like
matched for symptom class, coronary anatomy, EF and BP vs. a more complex non
COURAGE-like) and visit (baseline, 180 days, 365 days) as fixed factors and group
by visit as an interaction effect.
Results: See Table.
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Conclusion: This represents the first time that patient-reported outcomes have been
reported in both COURAGE-like and non COURAGE-like patients exclusively
receiving a DES. Although there were no differences in clinical outcomes, marked
improvements in patient’s health status were observed 12 months after XIENCE V.
QoL significantly improved with the two groups behaving similarly over time. There
were consistent improvements in QoL across all angina burden cohorts with
improvements occurring early, being sustained for 1 year and most notable when angina
burdens were greatest. These data extend patient’s perspectives on the benefits of PCI.
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Background: The PRO Kinetic Energy is a thin strut (60 μm) cobalt chromium alloy
(L605) bare metal stent, which is completely coated with a thin layer of amorphous
silicon carbide PROBIO. The aim of this registry is to evaluate the clinical performance
of the PRO-Kinetic Energy stent system in a large patient population in standard
clinical care.
Methods: Between April 09, and November 09, 2010, 1’016 subjects presenting with
de-novo and re-stenotic coronary artery lesions were consecutively enrolled in this
international, multicentric ENERGY Registry. Primary safety endpoint was MACE
(composite of cardiac death, clinically driven TLR, myocardial infarction and acute
myocardial infarction) at six-month follow-up. Additional follow-up assessments are
defined in the protocol for 12 and 24 months. Quality of Life (EQ-5D) evaluation will
be performed in a subgroup on all follow-up intervals. Following subgroups were pre-
specified: diabetes, AMI, unstable angina, small vessel (< 2.75 mm) and elderly
patients (> 75 yrs).
Results: Seven hundred eighty-nine men (78%) with a mean age of 66 ± 12.5, ranging
from 27 - 96 years, were enrolled in 48 sites in 10 countries. The majority of the
subjects presented with hypertension (71%), hyperlipidemia (68%) smoker (31%),
diabetes (16%). Fourteen percent of the patients experienced unstable angina. ACS
due to MI was seen in 452 patients. The portion of elderly patients is represented by
19%. Type A (21%), B1 (40%), B2 (29%) and C (10%) lesions were seen in this cohort.
Eighty-six percent (874/1016) follow up compliance at six-month follow-up was
achieved. MACE (hierachical) occurred in 4.7% subjects between baseline and 6-
month follow-up including 2.5% target lesion revascularizations,2.3% stent
thrombosis, 1.5% myocardial infarctions (incl. AMI) and 0.7% cardiac death.
Conclusion: New generation bare metal stents (BMS) like the PRO-Kinetic Energy
with very thin struts and passive coating show a very low rate of MACE compared to
previous BMS. Utility of such modern BMS platforms are still very relevant in the era
of DES.
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Background: The minimally invasive direct coronary artery bypassing (MIDCAB)
has proven its superiority over bare metal stenting of proximal left anterior descending
(LAD) artery in reducing the need of repeated revascularizations. Nevertheless, the
long term outcome of percutaneous coronary intervention (PCI) utilizing new
generation of drug eluting stenting (DES), in this lesion subset is unknown.
Methods: This is a multicenter retrospective registry of 463 consecutive patients,
enrolled between 2004 and 2009 with proximal, significant, type B and C LAD lesion
(>70% DS) who underwent either PCI with exclusive use of DES (72% of 2nd.
generation) or MIDCAB. We excluded patients with myocardial infarction (MI) on
admission, concomitant lesions in the right and/or circumflex coronary arteries,
previous PCI within 6 months, or previous CABG . A propensity score was utilized
for patients baseline characteristics matching and results adjustment.
Results: One hundred and eighty seven patients underwent PCI with DES while 276
MIDCAB. Patients in PCI group were older (63,6 ± 9,3 vs. 59,7 ± 10,2 y.o.; p<0,05),
more often female (32 vs. 21%; p<0,01) had higher CCS class (2,53 ± 0,9 vs. 2 ± 0,3;
p<0,01), higher Euroscore (4 vs. 2,2; p<0,01) and more often presented with peripheral
artery disease (8 vs. 2%; p<0,01). At 30 day follow up there was no death in both
groups. There were also no differences in the occurrence of major adverse
cardiovascular and cerebral events (MACCE) defined as death, stroke, myocardial
infarction or repeated revascularization between PCI and MIDCAB groups (0% vs.
0,7%;p=0,22). However there were less serious adverse events (SAE) defined as atrial
fibrillation, wound infection, low output syndrome or serious bleeding in patients who
underwent MIDCAB (0 vs. 5%; p<0,01). After adjustment at 5 year follow up there
were no differences in survival (93,5 vs. 95,7%; p=0,56), MACCE free survival (64,9
vs. 74,4%, p=0,12) and MI – free survival (94,9 vs. 95.8%; p=0,46) between PCI and
MIDCAB respectively. There was significantly higher freedom from repeated
revascularization in patients who underwent MIDCAB (86,4 vs. 64,1%; p=0,01).
Conclusion: Both procedures show exceptional safety, with no deaths and only minor
adverse events rate at periprocedural period. At long term PCI with DES is non inferior
to MIDCAB with regard to safety endpoints. The rate of repeated revascularizations
remained higher in the PCI group
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Background: Drug eluting stents (DES) of the first and second generation, differ in
their coating material which may have implications for the incidence of periprocedural
myocardial infarction (PMI). Our aim was to compare the incidence of PMI using the
revised Academic Research Consortium (ARC) definition of PMI between Taxus
Liberté, Endeavor Sprint, Endeavor Resolute and Xience V.
Methods: We assessed 800 patients treated with first (Taxus Liberté or Endeavor) or
second generation DES (Xience V or Resolute). Each DES group consisted of 200
consecutive patients, who were treated during the transition from first to second
generation DES. Routine peri-interventional assessment of cardiac biomarkers was
performed to compare the incidence of PMI between DES groups according to ARC:
2x upper reference limit of creatine kinase (CK), confirmed by CK-MB elevation.
Results: In 800 patients, a total of 1522 DES (363 Taxus; 385 Endeavor; 382 Xience
V; 392 Resolute) were implanted to treat 1232 lesions. Patient characteristics did not
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